Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000077.xml
Semin Thromb Hemost 2006; 32(1): 077-078
DOI: 10.1055/s-2006-933343
DOI: 10.1055/s-2006-933343
ERRATA
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.
The P2 Receptors and Congenital Platelet Function Defects
Further Information
Publication History
Publication Date:
15 February 2006 (online)
In the above-mentioned article, published in Seminars in Thrombosis and Hemostasis 2005; Volume 31, Number 2, pages 168-173, page 170, paragraph 1, line 3 should read:
P2Y12 is the target of efficacious antithrombotic agents like ticlopidine and clopidogrel,2,32 which are already used in clinical practice, and the AR-C compounds,33 one of which is currently under evaluation in clinical trials.
Professor
Marco Cattaneo
Unit of Hematology and Thrombosis, Ospedale San Paolo, DMCO University of Milan
Via di Rudinì, 8, 20142 Milan, Italy
Email: marco.cattaneo@unimi.it